Results 31 to 40 of about 128,640 (296)
Journal of Cardiovascular Development and Disease, 2023 Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou +10 more
doaj +1 more source
A walnut-containing meal had similar effects on early satiety, CCK, and PYY, but attenuated the postprandial GLP-1 and insulin response compared to a nut-free control meal. [PDF]
, 2017 Regular nut consumption is associated with lower adiposity and reduced weight gain in adulthood. Walnut feeding studies have observed minimal effect on body weight despite potential additional energy intake.
Barkai, Hava-Shoshana +4 more
core +2 more sources
Intra-islet glucagon-like peptide 1 [PDF]
Journal of Diabetes and its Complications, 2016 Glucagon-like peptide-1 (GLP-1) is originally identified in the gut as an incretin hormone, and it is potent in stimulating insulin secretion in the pancreas. However, increasing evidence suggests that GLP-1 is also produced locally within pancreatic islets.
Genevieve E. Fava +2 more
openaire +2 more sources
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. [PDF]
, 2015 © 2015 The Authors.Objective: Although Glucagon-like peptide 1 is a key regulator of energy metabolism and food intake, the precise location of GLP-1 receptors and the physiological relevance of certain populations is debatable.
Cork, SC +5 more
core +2 more sources
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
How glucagon-like is glucagon-like peptide-1? [PDF]
Diabetologia, 1984 Although glucagon-like peptide-1 has the appearance of a glucagon-homologue that may be co-secreted with glucagon, synthetic glucagon-like peptide-1-(1-37) does not significantly affect plasma glucose and insulin concentrations when administered at high doses (100 and 400 micrograms) to cortisone-pretreated rabbits.
M, Ghiglione +3 more
openaire +2 more sources
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes [PDF]
, 2003 Background Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of ...
McDonald Thomas J +2 more
core +2 more sources
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]
, 2014 Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core +1 more source
Physiological Reports, 2017 Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn +4 more
doaj +1 more source
Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
World Nutrition, 2019 There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj +1 more source